Announcing the arrival of Hervé Laouenan

McArthur and Associates GmbH are pleased to announce that Hervé Laouenan has joined the Association. Hervé is a senior project manager based near Bordeaux  experienced in project management in pharmaceutical companies across therapeutic indications from early to late-stage and mature products. His core expertise is the management of clinical projects. His work within biotechnology and medical devices brings experience and understanding of the requirements of portfolio management for projects at early stage where attention to assay validation and screening strategies is important. His experience extends also to the management of patient training programs, medical writing, and supporting large grant alliances.  He is the right person to support projects in complex environment requiring the agile coordination of multiple stakeholders to unify the efforts towards common goals.

Silvia Gatti-McArthur co-edited a series on Dopaminergic Alterations in Schizophrenia

Schizophrenia is a disabling pathology with a lifetime prevalence of approximately 1% worldwide and the etio-pathological mechanism(s) remain elusive. New therapies are also needed for the cognitive and negative symptoms of the disease which appear central to functional outcomes and yet poorly served by current therapies. The interesting topic issue Dopaminergic alterations in schizophrenia co-edited by S Gatti-McArthur, Andrew Grottick PM Llorca, JC Martel, Carol Tamminga, and Mark Tricklebank is now completed. A final editorial introduces the 10 outstanding contributions and provides a synthesis of the current knowledge regarding dopaminergic alterations in schizophrenia. The issue is the result of the collaboration of 3 participating journals Frontiers in Pharmacology (neuropharmacology section), Frontiers in Neuroscience (Neuropharmacology section), and Frontiers in Psychiatry (schizophrenia section). Few recent related issues have also appeared in the same journals and are reviewed in the editorial. They provide an important complement to this read and highlight specific areas of scientific progress.

Daniel Umbricht

McArthur and Associates is very pleased to welcome the addition of Dr Daniel Umbricht as an associate. Dr Umbricht received his MD at the University of Zürich, trained in general psychiatry at the Zucker Hillside Hospital in New York and specialized in clinical schizophrenia research. Dr Umbricht has held various senior and global positions at Novartis and Roche in Basel where he excelled in translational medicine, specifically neuropsychological and neurodevelopmental disorders. Dr Umbricht’s presence in McArthur and Associates GmbH significantly allows us to extend our range of specialized neuropharmacological consulting services to include early clinical development and translational medicine.

John Van Drie

McArthur and Associates is very pleased to welcome John Van Drie’s specialised experience applying in silico tools to structure-based drug discovery. Following graduate work at the California Institute of Technology, a fellowship at the Université Libre de Bruxelles, Brussels, Belgium. John has worked closely within the biopharmaceutical industry, academic groups and venture capitalists. 


 He has worked with Novartis both in Basel, Switzerland and was the director of the CADD group at Novartis in Cambridge MA. As a senior scientist in drug discovery, John has contributed to the oxazolidinone antibiotic research team at Vertex Pharmaceuticals in Boston MA as well at Pharmacia and Upjohn in Kalamazoo, MI. John was a member of the research team that discovered Abbott’s ritonavir, the first marketed HIV protease inhibitor for AIDS infections. He was a founding member of BioCad in Sunnyvale CA where he contributed to the development of the novel drug design software, Catalyst, which has since been marketed by Accelrys.


 His diverse industrial experience has enabled him to discover and co-invent novel molecular intellectual property and to help academic groups looking to turn their intellectual property into a form suitable for forming the basis of a startup. Further, John has worked closely with investors looking to invest in novel computational technology as well as novel drug discovery technology. His joining McArthur and Associates significantly expands our range of consulting services that we can offer to the biopharmaceutical industry and related investors.

Véronique Foutel

McArthur and Associates GmbH is happy to announce the recent addition of the biopharma strategic advisor,  Dr Véronique Foutel to our Team.  Dr Foutel brings with her extensive drug marketing and pricing experience. She has held various appointments with French pharmacovigilance and regulatory authorities, led global strategic functions within the Roche Pharma Division for 16 years, and is presently an executive committee member of a late-stage clinical biotech. Dr. Foutel’s academic qualifications include a PhD in Pharmaceutical Sciences, a graduate of the Stockholm School of Economics specializing in health economics, and the London Business School’s Roche executive leadership programme. Her expertise allows McArthur and Associates GmbH to offer services in strategic access planning, target profiling, value development, pricing, and interactions with EU and French regulatory bodies, Key opinion Leaders and payers.

Silvia Gatti-McArthur

McArthur and Associates GmbH is happy to announce that our Partner and Managing Director, Dr. Silvia Gatti-McArthur, has successfully completed the Diploma of Advanced Studies in Pharmaceutical Medicine course at the European Center of Pharmaceutical Medicine, University of Basel. The ECPM is a highly prestigious Institution providing continuing professional development within the pharmaceutical industry and associated professions.

McArthur and Associates Welcome the Expertise of Two New Associates

Dr Paolo Pevarello is a senior medicinal chemist with experience in academic and the biopharmaceutical industry. He is an author of over 60 papers and 53 patents. He is prepared to offer medicinal chemistry and intellectual property consulting on behalf of McArthur and Associates.


Mr Rolando Cassinari is a graphics designer with ample experience in preparing graphics content for scientific publications, conferences and other illustrations. He has worked in the milieu of scientific research institutions. Examples of his work may be accessed at ROLANDO CASSINARI Scientific illustrations.


McArthur and Associates GmbH believe in providing the right expertise to the biopharmaceutical industry

from the idea, bench, publication and registration.

We are committed to working together for science and human health.

Frontiers in Neuroscience Issue

May 21st 2020

Silvia Gatti-McArthur and colleagues have edited a research topic issue of Frontiers in Neuroscience entitled, Dopaminergic Alterations in Schizophrenia.

Topic editors: M.D. Tricklelbank, A.Grottick C.Tamminga, JC Martel PM Llorca and S. Gatti-McArthur

Schizophrenia is a disabling pathology with a lifetime prevalence of approximately 1% worldwide. The discovery of antipsychotics drugs that block the dopamine D2 receptor led to both improved disease management and to the dopamine hypothesis of schizophrenia, perhaps one of the most enduring in psychiatry. However, a clear understanding of the etiopathological mechanism(s) remains elusive. The contributions proposed for this Research Topic provide new paths for clinical and preclinical research.

Further information may be found at: